Citadel Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Citadel Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,700	Closed	-$15.1K	–	14360
2025 Q1	$15.1K	Sell	2,700 -3,700	-58%	-$32.4K	﹤0.01%	13335
2024 Q4	$51.6K	Buy	6,400 +5,700	+814%	+$52.3K	﹤0.01%	12361
2024 Q3	$7.17K	Buy	+700	New	+$6.92K	﹤0.01%	13379
2024 Q2	–	Sell	-7,700	Closed	-$106K	–	15070
2024 Q1	$106K	Buy	+7,700	New	+$91.5K	﹤0.01%	11273
2023 Q3	–	Sell	-1,800	Closed	-$14K	–	14859
2023 Q2	$14K	Sell	1,800 -5,600	-76%	-$31.8K	﹤0.01%	13020
2023 Q1	$42.2K	Buy	7,400 +2,600	+54%	+$13.6K	﹤0.01%	12377
2022 Q4	$28.3K	Sell	4,800 -15,900	-77%	-$53.7K	﹤0.01%	12806
2022 Q3	$66K	Sell	20,700 -1,700	-8%	-$6.81K	﹤0.01%	11426
2022 Q2	$100K	Buy	+22,400	New	+$89.4K	﹤0.01%	11414

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's ORIC Position: Q2 2026 in Review

Citadel Advisors increased its Oric Pharmaceuticals (ORIC) stake by 7.1% in Q2 2026, buying an estimated $1.56M and bringing the position to 2,595,299 shares worth $28.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Citadel Advisors first reported a position in ORIC in Q2 2020 and has held it in 20 quarters since. The position peaked at $30.7M in Q1 2026. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

Citadel Advisors held 2,595,299 shares of Oric Pharmaceuticals worth $28.1M as of Q2 2026.
Citadel Advisors bought 172,558 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
Oric Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2176 holding.
Citadel Advisors first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 20 quarters since.
Citadel Advisors's Oric Pharmaceuticals position peaked at $30.7M in Q1 2026.
180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.